Ticker: OCGN

Ocugen, Inc. (NASDAQ: OCGN) has recently reported its financial results for the quarter ending June 30, 2025, reflecting both progress and challenges as the company focuses on developing gene therapies for retinal diseases. Positive Aspects: Collaborative arrangement revenue increased to $1.373 ...

Ocugen, Inc. (NASDAQ: OCGN) Overview Ocugen is a biotechnology company primarily focused on developing and commercializing novel gene and cell therapies, biologics, and vaccines. Recent activities indicate ongoing clinical trials for its products, including OCU400, OCU410, and OCU200, aimed at tr...